Connect with us

Business

AXIM Biotechnologies Inc. (OTCMKTS: AXIM) Publishes in Journal of Clinical Virology about its Rapid SARS-CoV-2 Test

Published

on

AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has announced the publication of an article in the Journal of Clinical Virology detailing the development of a rapid COVID-19 neutralizing antibodies levels test. The company’s SARS-CoV-2 neutralizing antibody test is the first diagnostic that can measure functional neutralizing antibodies levels that prevent SARS-CoV-2 from entering cells of the host.

Antibody test requires a single fingerstick blood drop 

This is the first report of a fast test that can quantify neutralizing antibody levels semi-quantitatively. Most importantly, the test is small, cheap, and just requires a single drop of blood from a fingerstick. When compared to an authentic SARS-CoV-2 neutralization assay using serum samples from COVID-19 patients, the test has shown to have over 90% sensitivity with 100% specificity when conducted in a point-of-care environment or by an individual.

Notably, the test doesn’t react with sera from other seasonal viral respiratory infections that cause colds and flu-like symptoms in patients. The test’s ability to measure levels of neutralizing antibodies in vaccine recipients and previously infected individuals are also highlighted in the publication.

AUS associate professor and the publication’s lead author Dr. Douglas Lake said, “All antibodies are not created equal. Most antibody tests for COVID simply detect antibodies to either spike or nucleocapsid (viral core), but this test measures levels of functional antibodies: neutralizing antibodies–antibodies that prevent the virus from infecting cells. Neutralizing antibodies form a molecular force field in blood and tissues that prevent the virus from infecting cells.”

The rapid test enables people to monition neutralizing antibodies levels 

AXIM CEO John Huemoeller commented, “Since COVID-19 is not going away anytime soon, it is important to keep your levels of neutralizing antibodies high to prevent infection. Our test allows one to know and monitor his or her levels of neutralizing antibodies without sending a tube of blood to the lab for an expensive test. Our rapid test may impact public health because it indicates when protective antibodies are declining to pre-vaccine levels which might suggest a booster shot to prevent infection and potential spread of the virus.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES